Merck & Co.
MRK
$127.50
-0.10%
Merck & Co. is a global pharmaceutical leader developing therapies for cardiometabolic disease, cancer, and infections, with a substantial vaccine and animal health portfolio. Its immuno-oncology platform, anchored by the blockbuster Keytruda, and pediatric vaccines like Gardasil distinguish it as a top-tier innovator in the drug manufacturing industry. The current investor narrative centers on Merck's ability to navigate the looming patent cliff for Keytruda, offset by pipeline progress and recent FDA label expansions for its pneumococcal vaccine Capvaxive, while merger-and-acquisition activity in big pharma adds strategic uncertainty.…
MRK
Merck & Co.
$127.50
Related headlines
Investment Opinion: Should I buy MRK Today?
Rating: Buy. Thesis: Merck offers a compelling value opportunity with a 35% discount to the industry P/E, a strong 3.1% dividend yield, and a low beta, while the market overestimates the impact of the Keytruda patent cliff given the company's pipeline and vaccine portfolio. The consensus analyst rating is Buy with an average target of $132.78, implying 7.4% upside.
Supporting Evidence: Merck's trailing P/E of 14.4x is well below the industry average of 22.0x, and its forward P/E of 12.8x suggests expected earnings growth. Revenue grew 4.3% YoY in Q1 2026, and the TTM net margin of 28.1% demonstrates strong profitability. Free cash flow of $14.12 billion TTM supports the dividend and strategic investments. The analyst average target of $132.78 provides a clear upside catalyst, and the low beta of 0.205 offers downside protection.
Risks & Conditions: The biggest risks are the Keytruda patent cliff, which could accelerate revenue decline, and the potential for large one-time charges from acquisitions. This Buy rating would be downgraded to Hold if revenue growth turns negative or if the P/E expands above 18x without corresponding earnings growth. It would be upgraded to Strong Buy if the stock pulls back to $110 or if pipeline milestones (e.g., Capvaxive sales data) exceed expectations. Overall, Merck appears undervalued relative to its history and peers, offering a favorable risk/reward for long-term investors.
Sign up to view all
MRK 12-Month Price Forecast
Merck's current valuation at a 35% discount to the industry P/E appears to overstate the patent cliff risk, while the company's strong free cash flow and dividend provide a floor. The base case of steady but decelerating growth is most likely, with the stock trading near the analyst average target. However, the wide range of analyst targets (100-155) reflects genuine uncertainty. The bullish stance is supported by the attractive valuation and defensive characteristics, but confidence is medium due to the patent cliff overhang. An upgrade to high confidence would require visible pipeline catalysts, while a downgrade would follow negative revenue surprises.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $132.78 and implied upside of +4.1% versus the current price.
Average Target
$132.78
0 analysts
Implied Upside
+4.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$100 - $155
Analyst target range
Merck is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean rating 1.86 on a 1-5 scale, where 1 is Strong Buy). The average price target is $132.78, implying approximately 7.4% upside from the current price of $123.61. The distribution leans bullish, with no sell ratings in the recent institutional ratings data, which includes upgrades and reiterations from firms like BMO Capital, Guggenheim, and JP Morgan. The target range spans from a low of $100.00 to a high of $155.00, reflecting a wide dispersion of views. The high target of $155 assumes successful pipeline execution and market share gains in vaccines, while the low target of $100 prices in a sharper-than-expected decline in Keytruda sales and margin compression. The wide spread (55% difference between low and high) indicates elevated uncertainty around the company's growth trajectory. Recent analyst actions have been predominantly positive, with firms like B of A Securities and Scotiabank reiterating Buy ratings in late June 2026, suggesting confidence in the near-term outlook despite the patent cliff overhang.
Drowning in data?
Find the real signal!
Bulls vs Bears: MRK Investment Factors
Merck presents a classic value-versus-growth debate. On the bull side, the stock trades at a 35% discount to the industry P/E, offers a strong 3.1% dividend yield, and has a low beta that provides downside protection. Recent FDA label expansion for Capvaxive and a consensus Buy rating with 7.4% upside support the bullish case. On the bear side, the looming Keytruda patent cliff is the dominant overhang, with revenue growth already decelerating. The Q1 2026 net loss and wide analyst target range underscore elevated uncertainty. The single most important tension is whether Merck can offset Keytruda's revenue decline through pipeline successes (vaccines, new oncology drugs) and cost discipline. If pipeline execution falters, the stock could re-rate lower; if successful, the current low multiple offers significant upside. Currently, the evidence slightly favors the bull case given the attractive valuation and defensive qualities, but the patent cliff risk keeps the thesis balanced.
Bullish
- Attractive Valuation with 35% Discount to Peers: Merck's trailing P/E of 14.4x is well below the industry average of 22.0x, representing a 35% discount. This low multiple, combined with a forward P/E of 12.8x, suggests the market is pricing in significant headwinds, creating a potential value opportunity if the company successfully navigates the Keytruda patent cliff.
- Strong Free Cash Flow and Dividend Yield: Merck generated $14.12 billion in free cash flow over the trailing twelve months, providing a robust free cash flow yield of 5.4%. The dividend yield of 3.1% is well-supported by a payout ratio of 44.8%, offering a solid income component for investors.
- Recent FDA Label Expansion for Capvaxive: On June 18, 2026, the FDA expanded the label for Merck's pneumococcal vaccine Capvaxive to include at-risk children and adolescents. This expansion could solidify Merck's position in the vaccine market and drive incremental revenue, partially offsetting Keytruda's patent cliff.
- Low Beta Provides Defensive Characteristics: With a beta of 0.205, Merck is significantly less volatile than the broader market. This low correlation makes it a defensive holding during market downturns, as evidenced by its 51.6% one-year return versus the S&P 500's 20.9% gain.
Bearish
- Keytruda Patent Cliff Looms Large: Keytruda, Merck's top-selling drug, faces patent expirations in the late 2020s, which could lead to a significant revenue decline. Revenue growth has already decelerated from 8.6% YoY in Q3 2025 to 4.3% in Q1 2026, signaling the early impact of competition.
- Q1 2026 Net Loss Due to Large R&D Charge: Merck reported a net loss of $4.24 billion in Q1 2026, driven by a $12.56 billion R&D charge. While this is a one-time item, it highlights the risk of large impairment or acquisition-related costs that can distort earnings and cash flow.
- Elevated Uncertainty Reflected in Wide Target Range: Analyst price targets range from $100 to $155, a 55% spread that indicates deep uncertainty about Merck's growth trajectory. The low target of $100 implies a potential 19% downside from current levels, reflecting bearish scenarios around the patent cliff.
- High PEG Ratio Suggests Limited Growth Premium: Merck's PEG ratio of 1.81x, based on forward earnings, suggests that the stock is not cheap on a growth-adjusted basis. This implies that the market expects modest earnings growth, and any disappointment could lead to multiple compression.
MRK Technical Analysis
Merck is in a sustained uptrend, with the stock up 51.6% over the past year, significantly outperforming the S&P 500's 20.9% gain. The current price of $123.61 sits at 94.9% of its 52-week range ($76.66–$130.29), indicating the stock is near its highs and reflecting strong bullish momentum, though it also suggests limited near-term upside without a catalyst. Over the past three months, Merck has gained 7.1%, while the one-month return of 7.6% shows accelerating short-term momentum, diverging from the broader market's 0.6% monthly gain. This relative strength (6.98 over one month) signals that Merck is attracting strong buying interest, possibly driven by positive news flow such as the FDA label expansion for Capvaxive. However, the stock's beta of 0.205 indicates it is significantly less volatile than the market, meaning the rally is driven by company-specific factors rather than broad market moves. Key support lies at the 52-week low of $76.66, while resistance is at the 52-week high of $130.29. A breakout above $130.29 would signal a continuation of the uptrend, potentially targeting new highs, while a breakdown below $120 (recent consolidation zone) could trigger a pullback toward $115. Given the low beta, Merck offers a defensive profile with lower downside risk, but the elevated position within the range warrants caution for new entries.
Beta
0.20
0.20x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$77-$132
Price range past year
Annual Return
+56.4%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +10.4% | +0.3% |
| 3m | +7.1% | +4.7% |
| 6m | +17.2% | +7.5% |
| 1y | +56.4% | +18.4% |
| ytd | +19.8% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory remains solid, with Q1 2026 revenue of $16.29 billion, up 4.3% year-over-year, though growth has decelerated from the 8.6% YoY growth seen in Q3 2025. The Pharmaceutical segment, which generated $14.35 billion in Q1 2026, continues to drive the top line, while the Animal Health segment contributed $1.79 billion. The deceleration reflects the early stages of Keytruda's patent cliff, but the company's vaccine portfolio (including Gardasil and Capvaxive) provides diversification. Profitability metrics are mixed: gross margin remains strong at 81.9% in Q1 2026, but the company reported a net loss of $4.24 billion in that quarter due to a $12.56 billion R&D charge (likely an impairment or acquisition-related cost). Excluding this, operating income was positive in prior quarters (e.g., $6.16 billion in Q4 2025). The net margin over the trailing twelve months is 28.1%, indicating solid underlying profitability. The balance sheet is healthy, with a current ratio of 1.54 and a debt-to-equity ratio of 0.96, suggesting manageable leverage. Free cash flow over the trailing twelve months is $14.12 billion, providing ample liquidity for dividends and strategic investments. However, the Q1 2026 net loss and negative free cash flow of $2.93 billion (due to acquisition outflows) highlight the impact of large one-time charges on short-term financials.
Quarterly Revenue
$16.3B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$14.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Since net income is positive on a trailing twelve-month basis (despite the Q1 loss), we use the P/E ratio as the primary valuation metric. Merck's trailing P/E is 14.4x, while its forward P/E is 12.8x, implying the market expects earnings growth over the next year. The gap between trailing and forward P/E suggests a modest growth premium. Compared to the industry average P/E of 22.0x (estimated from sector data), Merck trades at a 35% discount, which may reflect concerns about the Keytruda patent cliff and pipeline uncertainty. However, the company's strong free cash flow yield (5.4% based on FCF/EV) and dividend yield of 3.1% provide a value floor. Historically, Merck's trailing P/E has ranged from 9.0x (Q3 2025) to 23.3x (Q4 2022), and the current 14.4x is near the lower end of its five-year range, suggesting the stock is undervalued relative to its own history. This low multiple could indicate that the market is pricing in significant headwinds, but it also presents a potential value opportunity if the company can successfully manage the patent cliff and deliver on pipeline milestones.
PE
14.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Merck's primary financial risk is the impending patent cliff for Keytruda, which accounted for a significant portion of revenue. Revenue growth has already slowed to 4.3% YoY in Q1 2026, and the company reported a net loss of $4.24 billion due to a $12.56 billion R&D charge. While the balance sheet is healthy (current ratio 1.54, debt-to-equity 0.96), the large one-time charge highlights the potential for earnings volatility from acquisitions or impairments. Free cash flow of $14.12 billion TTM provides a buffer, but negative free cash flow of $2.93 billion in Q1 2026 due to acquisition outflows is a concern.
Market & Competitive Risks: Merck's low beta of 0.205 means it is less correlated with the market, but it is not immune to sector rotation or regulatory headwinds. The stock trades at a 35% discount to the industry P/E, which could narrow if the patent cliff fears prove overblown, but could also widen if competition intensifies. Recent news highlights that big pharma is in a merger mania phase, and Merck's pipeline must compete with rivals like Eli Lilly in GLP-1s and vaccines. The FDA label expansion for Capvaxive is a positive, but Pfizer remains a strong competitor in the pneumococcal vaccine market.
Worst-Case Scenario: In a severe scenario, Keytruda sales could decline faster than expected due to biosimilar competition, and pipeline drugs fail to gain traction. This could drive the stock to the analyst low target of $100, representing a 19% decline from the current price of $123.61. The 52-week low of $76.66 would imply a 38% downside, but that level was reached during a broader market selloff and may not be repeated. Realistically, a 20-25% decline to $95-100 is plausible if earnings disappoint and the multiple contracts further.
FAQ
The primary risk is the Keytruda patent cliff, which could lead to a significant revenue decline as biosimilars enter the market. Revenue growth has already slowed to 4.3% YoY in Q1 2026. Second, large one-time charges, such as the $12.56 billion R&D charge in Q1 2026, can distort earnings and signal acquisition risks. Third, competitive pressure from rivals like Pfizer in vaccines and Eli Lilly in GLP-1s could limit market share gains. Finally, the wide analyst target range ($100-$155) reflects high uncertainty, and a bear-case scenario could see the stock fall 19% to $100. The low beta of 0.205 mitigates macro risk but does not eliminate company-specific headwinds.
The 12-month forecast is moderately bullish, with a base case target of $125-135 (50% probability) aligning with the analyst average of $132.78. The bull case (25% probability) targets $135-155, driven by pipeline success and Capvaxive growth. The bear case (25% probability) targets $100-115, assuming Keytruda declines faster than expected. The most likely scenario is steady but decelerating growth, with the stock offering a 7.4% upside to the average target. Key assumptions include Keytruda sales declining 2-4% annually and Capvaxive contributing $1.5 billion in revenue. The AI assessment is bullish with medium confidence, citing the attractive valuation and defensive profile.
Merck appears undervalued relative to both its peers and its own history. The trailing P/E of 14.4x is a 35% discount to the industry average of 22.0x, and the forward P/E of 12.8x suggests expected earnings growth. Historically, the stock has traded between 9.0x and 23.3x P/E over the past five years, and the current level is near the lower end of that range. The PEG ratio of 1.81x indicates that the market is not pricing in aggressive growth, but rather a modest recovery. The low valuation implies that the market is already discounting the Keytruda patent cliff, creating a potential value opportunity if the company can successfully diversify.
Merck is a good buy for long-term, income-oriented investors seeking a defensive position with a 3.1% dividend yield and low beta of 0.205. The stock trades at a 35% discount to the industry P/E (14.4x vs 22.0x), and the average analyst target of $132.78 implies 7.4% upside. However, the Keytruda patent cliff is a significant risk, and the Q1 2026 net loss of $4.24 billion highlights earnings volatility. For investors with a 3-5 year horizon who believe in Merck's pipeline, the current valuation offers a favorable entry point. Short-term traders may find limited upside near the 52-week high of $130.29.
Merck is best suited for long-term investment, given its low beta of 0.205, strong dividend yield of 3.1%, and value-oriented valuation. The stock's defensive characteristics make it a core holding for conservative portfolios, with a suggested minimum holding period of 3-5 years to ride out the Keytruda patent cliff. Short-term traders may find limited upside near the 52-week high of $130.29, and the low volatility (beta 0.205) reduces trading opportunities. However, the recent 7.6% one-month gain and relative strength of 6.98 indicate short-term momentum, which could be exploited by active traders. Overall, long-term investors are better positioned to benefit from the dividend and potential multiple expansion.
